We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Metastatic Prostate Cancer Patients Monitored by CTCs

By Labmedica staff writers
Posted on 04 Mar 2008
A diagnostic test automates the detection and enumeration of circulating tumor cells (CTCs), cancer cells that detach from solid tumors and enter the blood stream. More...
The system's specificity, sensitivity, and reproducibility allow for serial assessment of CTCs as early as the first cycle of treatment to help evaluate disease progression sooner.

The test uses antibodies that are joined to microscopic iron particles, called ferrofluid. These antibody/ferrofluid combinations attach very specifically to CTCs. Powerful magnets then "pull” the CTCs out of the blood sample, and they are then stained with additional biomolecules and chemicals so that they can be positively identified as CTCs.

Called the CellSearch system, the test was developed by Veridex LLC (Warren, NJ, USA), a Johnson and Johnson company. The system has been approved by the U.S. Food and Drug Administration (FDA; Rockville, MD, USA) as an aid in the monitoring of metastatic prostate cancer (MPC) patients. The system is currently used for breast cancer and colorectal cancer patients to predict progression-free survival and overall survival in patients. The results of serial testing for CTCs with the CellSearch system provide additional information to the oncologist earlier than other currently approved diagnostic modalities, thereby allowing the oncologist to make more-informed patient care decisions.

According to the American Cancer Society, prostate cancer claims approximately 27,000 lives each year, the vast majority of which are a result of recurrent metastatic disease. Currently, oncologists often have to wait several months before they can determine if a specific treatment is beneficial to the patient. The CellSearch system helps physicians to predict disease progression and patient survival any time during therapy.

A prospective, multi-center clinical trial was conducted to validate the expanded clearance for CellSearch. The study, which took place in 65 clinical centers in the United States and Europe, involved 231 metastatic prostate cancer patients about to enter first- or later-line chemotherapy. Data showed that patients with less than five CTCs at baseline had significantly better survival rates versus patients with more than five CTCs. Data also showed that CTCs are a strong independent predictor of progression-free survival and overall survival, and that the combination of CTC analysis and prostate-specific antigen (PSA) assessment may provide the most accurate assessment of prognosis.

Dr. Nick Vogelzang, from the Nevada Cancer Institute (Las Vegas, NV, USA), said, "We have compared CellSearch CTC test results to the standard clinical and biomedical parameters, such as prostate specific antigen [PSA] measured in MPC [metastatic prostate cancer] patients. A decrease in the number of CTCs is most often associated with patients successfully responding to therapy. Further analysis of CTCs may provide information as to the most efficacious treatments for specific individuals.


Related Links:
Veridex
U.S. Food and Drug Administration
Nevada Cancer Institute

New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.